We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Gives Nod to Celgene’s Arthritis Drug Otezla
The UK’s price watchdog is backing Celgene’s Otezla as a standalone or combined treatment for active psoriatic arthritis when other options are ineffective or not tolerated, provided the company discounts its price.